Valneva begins phase III COVID-19 vaccine trial

By The Science Advisory Board staff writers

Valneva announced it has initiated a phase III trial to evaluate its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company's Cov-Compare trial will pit VLA2001 against AstraZeneca's conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial.

The U.K. trial will enroll 4,000 participants who will receive two doses of either vaccine. The primary end point of Cov-Compare will be to determine immune response two weeks after completion of a two-dose immunization schedule administered in a four-week interval.

Pending results, Valneva plans to submit the vaccine for initial approval later this year, the company stated.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking